Timber Pharmaceuticals Inc News - TMBR

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American:...

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or...

Timber Pharmaceuticals to be Acquired by LEO Pharma

Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through...

Timber Pharmaceuticals Discloses Communication From NYSE American

WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or...

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate...

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70...

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ...

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for...

Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology

- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Timber Pharmaceuticals Inc (TMBR)

Professional-Grade Tools, for Individual Investors.

TMBR News

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

Timber Pharmaceuticals to be Acquired by LEO Pharma

Timber Pharmaceuticals Discloses Communication From NYSE American

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology

Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis

Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook

Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

Current Report Filing (8-k)

Current Report Filing (8-k)

TMBR Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Timber Pharmaceuticals Inc (TMBR) News

Timber Pharmaceuticals Inc (TMBR)

Professional-Grade Tools, for Individual Investors.

TMBR News

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

Timber Pharmaceuticals to be Acquired by LEO Pharma

Timber Pharmaceuticals Discloses Communication From NYSE American

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology

Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis

Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook

Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

Current Report Filing (8-k)

Current Report Filing (8-k)

TMBR Discussion

Your Recent History